Art Pappas will join the panel, "The Research, Funding and Product Continuum" at the Southeast Venture Philanthropy Summit.

Art Pappas joins a panel at the 2013 BIO International Convention in Chicago titled, "Money Ball - Winning Venture Strategies."

Chimerix, a Durham, N.C.-based biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, has appointed Ernest Mario, Ph.D., as chairman of its board of directors.

During the course of his career, Mario has served as the CEO, chairman and a director of several pharmaceutical companies. From 1989 to 1993, he served as chief executive of Glaxo Holdings, then the second-largest drug company in the world. Mario led drug delivery technology company ALZA from 1993 until its acquisition by Johnson & Johnson in 2001. He served as chairman and CEO of Reliant Pharmaceuticals from 2003 until its acquisition by GlaxoSmithKline in 2007. He also previously served as the chairman of multinational CRO Pharmaceutical Product Development (PPD) from 1993 to 2011.

Mario currently serves as chairman and CEO of Capnia, a privately held pharmaceutical company, as well as chairman of the American Foundation for Pharmaceutical Education.

Art Pappas will join the panel, "How the Other Half Lives: What's Happening in Venture and Why it Matters" at the BIO CEO Investor conference.

RALEIGH, N.C. – January 25, 2013 – LipoScience, Inc.(NASDAQ:  LPDX) today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a price to the public of $9.00 per share.  The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol "LPDX" on Friday, January 25, 2013.  All of the shares are being offered by LipoScience. In addition, LipoScience has granted the underwriters a 30-day option to purchase an aggregate of up to an additional 750,000 shares at the initial public offering price, less underwriting discounts and commissions, to cover over-allotments. LipoScience, Inc. expects to receive, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, net proceeds of approximately $38.6 million from the offering and intends to use the net proceeds to hire additional sales and marketing personnel and to support costs associated with increased sales and marketing activities, for capital expenditures,including components of the Vantera® system, to fund its research and development programs, including the expansion of its diagnostic test menu based on the Vantera system, to pay accrued dividends in the amount of $5.2 million on shares of preferred stock that will convert into common stock upon the closing of the offering, and the balance for other general corporate purposes, including general and administrative expenses, working capital and the potential repayment of indebtedness.

NOVATO, CA –January 10, 2013— Ultragenyx Pharmaceutical Inc., a biotechnology company focused on the development of treatments for rare and ultra-rare genetic disorders, announced that it has in-licensed rights for triheptanoin,  a promising treatment for long-chain fatty acid oxidation disorders (FAOD), from Baylor Research Institute in Dallas, TX. Triheptanoin is intended as a substrate replacement therapy to restore deficient intermediates in the mitochondria and to enable energy metabolism in patients with FAOD and potentially other genetic metabolic disorders.

NEW YORK--LipoScience Inc. set terms for its initial public offering Thursday, with the diagnostics company looking to raise as much as $75 million and become the first health-care company to go public this year.

The company said in a filing with the Securities and Exchange Commission that it expects to fetch between $13 and $15 each for its five million shares.

The company develops medical diagnostic tests and analytics tools. Its key product measures low-density lipoprotein, or LDL, particles in blood. The particles can provide clues about heart disease.

NOVATO, CA – December 20, 2012 - Ultragenyx Pharmaceutical Inc., a biotechnology company focused on the development of treatments for rare and ultra-rare genetic disorders, today announced the successful completion of a $75 million Series B round financing led by Adage Capital Partners, LP.  Joining Adage as new investors in this financing are mutual funds and separate account clients advised by T. Rowe Price Associates, Inc., Jennison Associates LLC (on behalf of clients), funds and accounts under management by subsidiaries of BlackRock, Inc., Sanofi-Genzyme BioVentures, Shire plc and additional blue chip public market funds.  Existing investors, TPG Biotech, Fidelity Biosciences, HealthCap and Pappas Ventures also participated in the transaction.

Click here to read the full press release.

PHILADELPHIA—(November 16, 2012) – The Wistar Institute recently welcomed Van Billet, Joseph Goldblum and Art Pappas to its board of trustees.

Art Pappas has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. Currently, he serves as managing partner at Pappas Ventures, a life sciences venture capital firm with more than $300 million in capital under management. The firm has invested in over 50 biotechnology, biopharmaceutical, specialty pharmaceutical, drug delivery and medical device companies throughout the U.S.

Prior to founding Pappas Ventures in 1994, Pappas held a number of senior level leadership positions at several multinational pharmaceutical companies. He served as chief executive for international operations and as an executive member of the board of directors of Glaxo Holdings PLC, and served as vice president of commercial operations for Abbott International Ltd. He also held various executive and general management positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally.

Pappas currently serves on the board of directors for Afferent Pharmaceuticals, CardioDx, Chimerix and TyRx Pharma. He was the founding CEO and is current chairman of CoLucid Pharmaceuticals.

Pappas serves on the North Carolina Biotechnology Center's Board of Directors and is a member of the National Venture Capital Association (NVCA) Medical Industry Group Advisory Board. A decorated Vietnam veteran, Pappas served as an officer in the US Army 101st Airborne Division and the Special Forces.

The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has long held the prestigious Cancer Center designation from the National Cancer Institute. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. The Wistar Institute: Today’s Discoveries – Tomorrow’s Cures. On the Web at www.wistar.org.

Click Here to read the full press release